Published in Int J Colorectal Dis on September 02, 2007
Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach. Curr Drug Targets (2011) 1.53
Diagnosis and management of microscopic colitis. World J Gastroenterol (2008) 1.24
A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol (2010) 1.20
Diagnosis and management of microscopic colitis: current perspectives. Clin Exp Gastroenterol (2014) 1.15
Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer (2011) 0.95
Neuroprotection by acetyl-11-keto-β-Boswellic acid, in ischemic brain injury involves the Nrf2/HO-1 defense pathway. Sci Rep (2014) 0.92
Frankincense: systematic review. BMJ (2008) 0.91
Recent advances in diagnosis and treatment of microscopic colitis. Ann Gastroenterol (2011) 0.84
Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines: a meta-analysis. World J Gastroenterol (2013) 0.84
Microscopic colitis. World J Gastroenterol (2012) 0.81
Boswellia serrata Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage. PLoS One (2015) 0.81
Noninfectious colitides: collagenous colitis, lymphocytic colitis, diversion colitis, and chemically induced colitis. Clin Colon Rectal Surg (2007) 0.80
Microscopic colitis (lymphocytic and collagenous), eosinophilic colitis, and celiac disease. Clin Colon Rectal Surg (2015) 0.80
Naringin ameliorates acetic acid induced colitis through modulation of endogenous oxido-nitrosative balance and DNA damage in rats. J Biomed Res (2013) 0.79
NOD2/CARD15 gene polymorphisms are not associated with collagenous colitis. Int J Colorectal Dis (2006) 0.78
Systemic Redox Imbalance in Chronic Kidney Disease: A Systematic Review. Oxid Med Cell Longev (2016) 0.76
Optimal management of collagenous colitis: a review. Clin Exp Gastroenterol (2016) 0.75
Review of Anti-Inflammatory Herbal Medicines. Adv Pharmacol Sci (2016) 0.75
Lymphocytic ("microscopic") colitis: a comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol (1989) 3.02
Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology (1991) 2.93
Collagenous colitis and fecal stream diversion. Gastroenterology (1995) 2.32
Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol (1999) 2.32
Microscopic colitis syndrome. Gut (1995) 1.98
Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. Aliment Pharmacol Ther (2005) 1.77
Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology (2002) 1.72
Collagenous colitis in Orebro, Sweden, an epidemiological study 1984-1993. Gut (1995) 1.64
Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther (1992) 1.63
Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. Phytomedicine (2003) 1.59
Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci (2002) 1.55
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology (2002) 1.55
Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut (2003) 1.47
Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res (1998) 1.42
Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol (1995) 1.31
Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med (2001) 1.27
Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res (1997) 1.23
Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. Dig Dis Sci (1992) 1.19
Collagenous colitis: jejunal and colorectal pathology. J Clin Pathol (1992) 1.12
[Therapy of active Crohn disease with Boswellia serrata extract H 15]. Z Gastroenterol (2001) 1.12
Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther (2005) 1.08
[Is H15 (resin extract of Boswellia serrata, "incense") a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study]. Z Rheumatol (1998) 1.07
Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. Mol Pharmacol (2000) 1.06
Collagenous and lymphocytic colitis: a clinical and histopathological review. Can J Gastroenterol (2000) 1.05
Microscopic colitis: an update. Inflamm Bowel Dis (2004) 1.02
Collagenous gastroduodenitis on collagenous colitis. Endoscopy (1990) 1.02
Autoantibodies and immunoglobulins in collagenous colitis. Gut (1996) 0.99
Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis (2001) 0.98
Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis (2004) 0.93
Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem (1998) 0.86
Collagenous colitis and lymphocytic colitis. J Clin Gastroenterol (2000) 0.86
5-Lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid (AKBA) by a novel mechanism. Phytomedicine (1996) 0.83
Interventions for treating collagenous colitis. Cochrane Database Syst Rev (2005) 0.77
Time to remission with budesonide in collagenous colitis. Aliment Pharmacol Ther (2005) 0.75
Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 5.77
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology (2003) 5.11
Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc (2007) 4.28
Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology (2007) 4.09
In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol (2006) 3.69
Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol (2008) 3.27
Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol (2006) 3.18
Ablation of nonneoplastic Barrett's mucosa using argon plasma coagulation with concomitant esomeprazole therapy (APBANEX): a prospective multicenter evaluation. Am J Gastroenterol (2006) 3.11
Venous thrombosis after long-haul flights. Arch Intern Med (2003) 2.50
A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc (2003) 2.47
Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One (2008) 2.46
Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology (2009) 2.16
High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol (2005) 2.13
Association between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease. Lancet (2002) 2.10
Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol (2004) 2.09
Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol (2009) 2.09
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology (2002) 2.06
Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut (2006) 1.92
Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood (2005) 1.90
Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology (2002) 1.72
Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol (2005) 1.72
T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood (2002) 1.71
Allele 2 of the interleukin-1 receptor antagonist gene is associated with early gastric cancer. J Clin Oncol (2004) 1.70
Functional analysis of the cag pathogenicity island in Helicobacter pylori isolates from patients with gastritis, peptic ulcer, and gastric cancer. Infect Immun (2004) 1.66
Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol (2006) 1.64
Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol (2006) 1.62
Diagnosing Helicobacter pylori in vivo by confocal laser endoscopy. Gastroenterology (2005) 1.59
The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol (2003) 1.56
Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis. J Med Microbiol (2006) 1.51
Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. Hum Genet (2002) 1.50
Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc (2003) 1.49
Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs (2006) 1.48
Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol (2008) 1.47
Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. Thromb Haemost (2012) 1.47
Evaluation of sensitivity and inter- and intra-observer variability in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus with enhanced magnification endoscopy. Scand J Gastroenterol (2006) 1.45
Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma: Results of a 196-patient series. Leuk Lymphoma (2006) 1.43
Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients. Eur J Gastroenterol Hepatol (2008) 1.42
Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol (2011) 1.41
The relevance of the detection of troponins to the forensic diagnosis of cardiac contusion. Forensic Sci Int (2005) 1.41
Progressive electroencephalogram frequency deceleration despite constant depth of propofol-induced sedation. Crit Care Med (2002) 1.40
Clinical and laboratory phenotypes associated with the aspirin-like defect: a study in 17 unrelated families. Br J Haematol (2008) 1.37
Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol (2013) 1.33
Open reduction and internal fixation versus closed treatment and mandibulomaxillary fixation of fractures of the mandibular condylar process: a randomized, prospective, multicenter study with special evaluation of fracture level. J Oral Maxillofac Surg (2008) 1.32
Confocal laser endomicroscopy for in vivo diagnosis of early squamous cell carcinoma in the esophagus. Clin Gastroenterol Hepatol (2007) 1.31
Open versus closed treatment of fractures of the mandibular condylar process-a prospective randomized multi-centre study. J Craniomaxillofac Surg (2006) 1.27
Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum (2006) 1.27
Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach. Gastric Cancer (2006) 1.26
A negative Helicobacter pylori serology test is more reliable for exclusion of premalignant gastric conditions than a negative test for current H. pylori infection: a report on histology and H. pylori detection in the general adult population. Scand J Gastroenterol (2005) 1.26
Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2008) 1.25
Haplotyping of STR cluster DXS6801-DXS6809-DXS6789 on Xq21 provides a powerful tool for kinship testing. Int J Legal Med (2005) 1.25
Validation of the STR DXS7424 and the linkage situation on the X-chromosome. Forensic Sci Int (2002) 1.24
Prevalence of Helicobacter pylori vacA, cagA and iceA genotypes in Nigerian patients with duodenal ulcer disease. J Med Microbiol (2002) 1.22
Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc (2005) 1.15
Identification of non-Helicobacter pylori spiral organisms in gastric samples from humans, dogs, and cats. J Clin Microbiol (2005) 1.15
Helicobacter pylori cag-Pathogenicity island-dependent early immunological response triggers later precancerous gastric changes in Mongolian gerbils. PLoS One (2009) 1.14
Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scand J Gastroenterol (2008) 1.14
Gastric-type adenocarcinoma of the duodenal second portion histogenetically associated with hyperplasia and gastric-foveolar metaplasia of Brunner's glands. Virchows Arch (2002) 1.13
Follow-up endoscopy in gastroenterology: when is it helpful? Dtsch Arztebl Int (2010) 1.13
Barrett's esophagus: histopathologic definitions and diagnostic criteria. World J Surg (2004) 1.10
Endoscopic resection of superficial esophageal squamous-cell carcinomas: Western experience. Am J Gastroenterol (2004) 1.09
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter (2011) 1.09
Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther (2005) 1.09
Argon plasma coagulation of cervical heterotopic gastric mucosa as an alternative treatment for globus sensations. Gastroenterology (2009) 1.03
Monoclonal gammopathy of undetermined significance and Russell body formation in Helicobacter pylori gastritis. Helicobacter (2006) 1.02
Why is the hyperplastic polyp a marker for the precancerous condition of the gastric mucosa? Virchows Arch (2005) 1.02
Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene (2004) 1.02
Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia (2007) 1.01
Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol (2011) 1.01
Pyloric gland adenoma arising in Barrett's esophagus with mucin immunohistochemical and molecular cytogenetic evaluation. Virchows Arch (2005) 1.01
Histology of microscopic colitis-review with a practical approach for pathologists. Histopathology (2015) 1.01
The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. Surg Endosc (2014) 1.00
DXS10079, DXS10074 and DXS10075 are STRs located within a 280-kb region of Xq12 and provide stable haplotypes useful for complex kinship cases. Int J Legal Med (2005) 0.99
Psychometric validation of the German translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in patients with reflux disease. Health Qual Life Outcomes (2003) 0.99
Resection of colorectal liver metastases: is a resection margin of 3 mm enough? : a multicenter analysis of the GAST Study Group. World J Surg (2008) 0.99
Pathology of early upper GI cancers. Best Pract Res Clin Gastroenterol (2005) 0.99
Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study. J Gastroenterol Hepatol (2007) 0.99
Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol (2002) 0.98
Is there an association of microscopic colitis and irritable bowel syndrome--a subgroup analysis of placebo-controlled trials. World J Gastroenterol (2005) 0.97
Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia. Eur J Haematol (2008) 0.96
Role of tumor necrosis factor alpha in Helicobacter pylori gastritis in tumor necrosis factor receptor 1-deficient mice. Infect Immun (2002) 0.94
Long-term results of endoscopic resection in early gastric cancer: the Western experience. Am J Gastroenterol (2009) 0.94
DXS10011: studies on structure, allele distribution in three populations and genetic linkage to further q-telomeric chromosome X markers. Int J Legal Med (2004) 0.93
Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis (2004) 0.93
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter (2008) 0.93